- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Seres Therapeutics is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.70 – a decrease of 7.53% over the previous week. Seres Therapeutics employs 233 staff and has a trailing 12-month revenue of around $374,000.
Our top picks for where to buy Seres Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Seres Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – MCRB. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Seres Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Seres Therapeutics stock price (NASDAQ: MCRB)
Use our graph to track the performance of MCRB stocks over time.Seres Therapeutics shares at a glance
Information last updated 2024-10-25.
| Latest market close | $0.70 |
|---|---|
| 52-week range | $0.54 - $2.05 |
| 50-day moving average | $0.90 |
| 200-day moving average | $0.95 |
| Wall St. target price | $3.89 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.19 |
Is it a good time to buy Seres Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Seres Therapeutics price performance over time
Historical closes compared with the close of $0.7049 from 2024-10-25
| 1 week (2024-10-22) | -9.92% |
|---|---|
| 1 month (2024-09-30) | -25.49% |
| 3 months (2024-07-30) | -44.06% |
| 6 months (2024-04-30) | -28.84% |
| 1 year (2023-10-30) | -51.39% |
|---|---|
| 2 years (2022-10-28) | -91.27% |
| 3 years (2021-10-29) | 6.08 |
| 5 years (2019-10-30) | 3.55 |
Seres Therapeutics financials
| Revenue TTM | $374,000 |
|---|---|
| Gross profit TTM | $-165,792,000 |
| Return on assets TTM | -27.1% |
| Return on equity TTM | -538.57% |
| Profit margin | 0% |
| Book value | $-0.57 |
| Market Capitalization | $128.8 million |
TTM: trailing 12 months
Seres Therapeutics share dividends
We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.
Seres Therapeutics share price volatility
Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $0.54 up to $2.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 2.015. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Seres Therapeutics overview
Seres Therapeutics, Inc. , a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.
Frequently asked questions
What percentage of Seres Therapeutics is owned by insiders or institutions?Currently 13.202% of Seres Therapeutics shares are held by insiders and 41.264% by institutions. How many people work for Seres Therapeutics?
Latest data suggests 233 work at Seres Therapeutics. When does the fiscal year end for Seres Therapeutics?
Seres Therapeutics's fiscal year ends in December. Where is Seres Therapeutics based?
Seres Therapeutics's address is: 101 Cambridgepark Drive, Cambridge, MA, United States, 02140 What is Seres Therapeutics's ISIN number?
Seres Therapeutics's international securities identification number is: US81750R1023 What is Seres Therapeutics's CUSIP number?
Seres Therapeutics's Committee on Uniform Securities Identification Procedures number is: 81750R102
More resources on Finder
More guides on Finder
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
SoFi Invest vs. Robinhood
Compare pros, cons, research tools and reviews for these two trading platforms.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
SoFi Invest® review 2024: Simple investing, free CFP access
SoFi Invest is a commission-free platform with both active and automated investment accounts.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
How to Invest $20K: 8 Ways to Maximize Earnings
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
-
Robinhood Review 2024: IRA Match and No Commissions
A deep dive into the highlights and limitations of Robinhood.
Ask a question